Test BackgroundFISH involves the application of fluorescent DNA probes specific to genes or genetic regions of interest that highlight abnormalities involving these regions.
In plasma cell neoplasms, a panel of FISH probes is applied at diagnosis to purified CD138+ plasma cells to identify common genetic abnormalities that are known to be strongly associated with prognosis in multiple myeloma and may assist in devising the most suitable management strategy.
The PCN FISH panel includes the following probes:
• TP53 17p13
• 9q/15q (to identify hyperdiploidy)
• In cases with IGH rearrangement, reflex testing of common fusion genes associated with poor prognosis undertaken (IGH-FGFR3 and IGH-MAF)
Sample Required See notes section
Sample Volume Samples would not be rejected on the basis of small volume, however, 5 mL is ideal.
Turnaround Time Myeloma referrals are treated as routine; 95% should be reported within 21 calendar days according to national guidelines. Please note however that the average turn around for myeloma FISH in our laboratory is approximately 12 days.
Bone marrow in cytogenetic transport medium, lithium heparin or EDTA Samples which are non-sterile, clotted or collected in sodium citrate, fixative or saline are not suitable. To ensure appropriate analysis and interpretation it is important to provide clear and concise clinical information.